GlassScriptPhysician profile
Marvin Edwin Bishop
NPI 1518937523
$2,886.11
in general payments reported to CMS, 2019-2025
21 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $349 · 2021: $499 · 2022: $442 · 2023: $443 · 2024: $582 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.20 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $617.10 | 2022-2024 | Vtama |
| Ucb, INC. | $325.37 | 2021-2024 | Bimzelx |
| Epi Health, LLC | $268.58 | 2019-2020 | |
| Pfizer INC. | $265.61 | 2019-2022 | |
| Abbvie INC. | $233.63 | 2020-2024 | |
| Incyte Corporation | $215.42 | 2022-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $201.96 | 2021-2022 | |
| Amgen INC. | $133.13 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $117.21 | 2022 | |
| Botanix Sb INC | $112.73 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $93.71 | 2025 | Zerbaxa |
| Sensus Healthcare, INC. | $88.03 | 2021 | |
| Tandem Diabetes Care, INC. | $40.40 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Arcutis Biotherapeutics, INC. | $37.65 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.41 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.89 | 2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $22.15 | 2025 | Tremfya |
| Biofrontera INC. | $22.03 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ibsa Pharma INC. | $16.71 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.77 | 2025 | Nuzyra |
| Orexo US, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.